Over the last decade, gram-negative bacilli have reemerged as important pathogens in solid organ transplant (SOT) recipients (1) .While numerous factors likely contributed to this epidemiologic shift, the resurgence of gramnegative pathogens has coincided with the dissemination of multidrug resistance in Enterobacteriaceae and nonfermentative bacilli. In Enterobacteriaceae, resistance to expanded-spectrum b-lactam antibiotics is usually conferred by plasmid-encoded extended spectrum b-lactamases (ESBLs), and ESBL-containing isolates are typically resistant to other classes of antibiotics. Because carbapenems are highly resistant to ESBL-mediated hydrolysis, these agents are preferred for the treatment of invasive infection caused by these organisms (2) .
For that reason, the recent emergence of carbapenemhydrolyzing b-lactamases (carbapenemases) in Enterobacteriaceae represents a concerning threat to the treatment of invasive enterobacterial infections. While carbapenemase-producing Enterobacteriaceae (CP-E) are rare in most parts of the world, certain geographic areas have seen signi¢cant outbreaks that may soon approach endemicity in some hospitals. In the northeastern United States and Israel, the plasmid-encoded Ambler class A serine b-lactamase Klebsiella pneumoniae carbapenemase (KPC) has been found in large institutional outbreaks of multidrug-resistant Klebsiella and Enterobacter species (3^5). In southern Europe, the Ambler class B metallo-blactamase VIM-1 has been associated with multiple genera outbreaks of gram-negative pathogens (6^8). Recent reports suggest that KPC-producing Enterobacteriaceae may be rapidly spreading across North America, while metallo-b-lactamase-producing Enterobacteriaceae are being reported in many locations worldwide (9^11). SOT recipients are vulnerable to infection by multidrug-resistant bacteria because of their underlying end-stage organ failure combined with a major surgical procedure and the necessity of life-long immunosuppression. In this report, we describe the clinical and microbiologic features of CP-E infection in 2 liver transplant (LT) recipients caused by KPC-producing Klebsiella.
Materials and methods

Microbiology
Identi¢cation and antibiotic susceptibility testing was performed using the V|tek 2 system with the AST GN14 card (bioMe¤ rieux, Durham, North Carolina, USA). Minimum inhibitory concentrations (MICs) were determined by the microbroth dilution method in cation-adjusted MuellerHinton broth and the Kirby Bauer agar disk di¡usion method, in accordance with the Clinical and Laboratory Standards Institute guidelines (12) . Modi¢ed Hodge testing was performed as described previously (13) . Brie£y, a Mueller^Hinton agar plate was inoculated with a one-tenth dilution of the carbapenem-sensitive strain Escherichia coli ATCC 25922 adjusted to a McFarland 0.5 standard. A 10 -mg imipenem disk was then placed in the center of the plate and the scrutinized Klebsiella isolates were struck radially from the disk to the plate edge. Invagination of E. coli growth at interface between the Klebsiella streak and the imipenem zone of inhibition was read as a positive modi¢ed Hodge test (13) .
DNA techniques
Plasmid DNA was isolated from Klebsiella strains using the Qiagen Plasmid Midi Kit (Qiagen, Valencia, California, USA) using 601C prewarmed eluting bu¡er, as recommended by the manufacturer for large plasmid isolation. Polymerase chain reaction (PCR) ampli¢cation of the bla KPC gene was performed using previously reported primers and condition (14) . bla KPC veri¢cation and allele identi¢cation was performed by bidirectional DNA sequencing (Biomolecular Research Facility, University of V|rginia Health System, Charlottesville, V|rginia, USA).
Southern analysis
Plasmid DNAs were subjected to electrophoresis on a 0.6% Pulse F|eld Certi¢ed Agarose (Bio-Rad Laboratories, Hercules, California, USA) gel using the following parameters: 0.5 Â TBE, 70 V, 41C, 20 h. The gel was stained with ethidium bromide and migration distances of the DNA bands from the clinical isolates were compared with reference plasmid DNAs from E. coli strain V517. Plasmid DNA was transferred to Amersham Hybond N 1 nylon membrane (GE Healthcare, Piscataway, New Jersey, USA) by capillary transfer and hybridized with a 1009 -bp DNA amplicon of bla KPC-2 labeled using the Amersham ECL Direct Nucleic Acid Labeling and Detection System (GE Healthcare) in accordance with the manufacturer's instructions.
Pulse-¢eld gel electrophoresis (PFGE)
PFGE of XbaI-digested total DNAwas performed using the PulseNet protocol for E. coli and other Enterobacteriaceae (15) . PFGE pro¢le analysis and dendrogram construction were performed using BioNumerics software (Applied Maths, Austin,Texas, USA).
Case reports
Case 1
A 45 -year-old man with decompensated liver disease resulting from hepatitis C virus infection and alcoholic cirrhosis underwent liver transplantation at our center in July 2007.The patient had been discharged from a Philadelphia hospital 4 days before LT after a 9 -day hospitalization for spontaneous bacterial peritonitis due to E. coli. LT was performed using the piggyback technique with duct-to-duct biliary anastomosis without complication; tazobactam-piperacillin (TZP) was given for perioperative antibiotic prophylaxis. Peritoneal £uid obtained during the transplant grew vancomycin-resistant Enterococcus faecium (VRE). The patient was discharged on prophylactic immunosuppression (tacrolimus with trough levels of 51 0 ng/mL, mycophenolate mofetil [MMF] , and a steroid taper), prophylactic trimethoprim-sulfamethoxazole (TMP-SMX), and a 2-week course of linezolid on postoperative day 7. Two weeks later, he was readmitted to a Philadelphia hospital with increasing ascites and abdominal pain. His condition rapidly deteriorated and he was transferred to our hospital within 48 h, where he was diagnosed with an anastomotic bile leak, peritonitis due to linezolid-resistant E. faecium (LRE) and Candida glabrata, and hepatic artery thrombosis. He underwent exploratory laparotomy and washout, endoscopic retrograde cholangiopancreatography with multiple biliary stent deployments, and unsuccessful attempts at hepatic artery stenting. Over the next 2 weeks, additional complications arose including cytomegalovirus (CMV) hepatitis, Aspergillus fumigatus and ventilator-associated pneumonia, tacrolimus toxicity, acute kidney injury requiring renal replacement therapy, pancytopenia, and luminal gastrointestinal (GI) bleeding. Antimicrobial therapy during this period included tigecycline, cipro£oxacin, anidulafungin, voriconazole, and ganciclovir; MMF was discontinued.
On hospital day 21, the patient became septic and K. pneumoniae grew from blood (strain Kpn1014), urine, abdominal drainage, and bronchial cultures. Antibiotic susceptibilities by V|tek 2 were notable for a meropenem MIC of 0.25 mg/mL (Table 1) . LRE was also isolated from the blood. Meropenem and daptomycin were started and tigecycline was stopped. Despite initial improvement, the patient again developed septic shock and multiorgan dysfunction 12 days later, while still receiving meropenem. K. pneumoniae (strain Kpn1016) was cultured from abdominal drain cultures, while Klebsiella oxytoca was isolated from both abdominal drain cultures (strain Kox1015) and respiratory secretions. The K. oxytoca isolate had a V|tek meropenem MIC of 1 mg/mL, and the K. pneumoniae isolate had aV|tek meropenem MIC of ! 16 mg/mL (Table 1) . Imaging studies and a second exploratory laparotomy failed to identify any undrained purulent collections. Kox1015 was initially interpreted as meropenem susceptible; however, the elevated meropenem MIC in strain Kpn1016 raised concern for the presence of carbapenemase, which previously had not been observed in any clinical Enterobacteriaceae isolates at our medical center. Molecular studies con¢rmed the presence of bla KPC-2 in both Kpn1016 and Kox1015. Meropenem was discontinued and a 2-week course of colistimethate sodium (colistin) and tigecycline was given. Isolation of carbapenemase-producing Klebsiella triggered a hospital-wide epidemiology surveillance program and updated infection control training programs for transplant and intensive care unit (ICU) healthcare sta¡. The patient remained critically ill and the bile leak was not amenable to repair by interventional radiology or surgery. Over the next several months, he developed a large liver abscess and had several episodes of bacteremia with KPC-producing K. pneumoniae as well as Stenotrophomonas maltophilia, Enterococcus faecalis, and E. faecium. Multiple courses of culture-directed antibiotics, including combinations of colistin, tigecycline, amikacin, high-dose TMP-SMX, and daptomycin, were given. On hospital day 115 (post-LTday 138), his clinical condition was deemed to be su⁄ciently stable to attempt re-LTas a ¢nal attempt for cure. The original graft was necrotic with several large abscesses. Intraoperatively the patient developed a severe coagulopathy and refractory hypotension despite massive resuscitation e¡orts, and he died several hours after graft reperfusion. MIC, minimum inhibitory concentration; n/d, not determined; PCR, polymerase chain reaction. 
Case 2
A 64 -year-old woman underwent LT for end-stage liver disease due to nonalcoholic steatohepatitis and hepatocellular carcinoma at our center in August 2007. LT was performed using the piggyback technique with ductto-duct biliary anastomosis without complications, and she was admitted to the same surgical intensive unit as Patient 1. TZP was given perioperatively. Prophylactic immunosuppression included tacrolimus (trough levels, 5^10 ng/mL), MMF, and corticosteroids. Initial graft function was poor and she developed steroid-resistant acute cellular rejection, which responded to anti-thymocyte globulin. On postoperative day 14, she developed a large pulmonary embolism with hemodynamic instability. Subsequent problems over the next month included GI bleeding, CMV viremia, Clostridium di⁄cile colitis, VRE bacteremia, and acute kidney injury requiring renal replacement therapy. Antimicrobial therapy during this period included linezolid, cefepime, metronidazole, ganciclovir, and prophylactic TMP-SMX; she did not receive a carbapenem. She slowly improved until post-LT day 45, when she developed septic shock and respiratory failure. K. pneumoniae was isolated from blood (strain Kpn1017 ) and urine cultures. The meropenem MIC was 4 mg/mL by V|tek 2, which was interpreted as susceptible. Meropenem was started and subsequent blood cultures were negative; however, she remained febrile and hypotensive, requiring inotropic support. F|ve days later, Kpn1017 was con¢rmed to be modi¢ed Hodge test and bla KPC PCR positive, and meropenem was changed to colistin. She responded well to a 2-week course of colistin; unfortunately, graft function further deteriorated when K. pneumoniae bacteremia and septic shock recurred several weeks later. Because of her multiple medical problems, re-LT was not an option and she died within days of withdrawal of intensive medical care.
Microbiology
Carbapenem susceptibilities and genetic analysis of the Klebsiella isolates are presented in Table 1 . Kpn1014, the initial K. pneumoniae isolate from Patient 1, had a meropenem MIC 0.25 mg/mL by V|tek 2 and microbroth dilution and a zone diameter of 28 mm by disk di¡usion. The isolate had a negative modi¢ed Hodge test and the bla KPC gene was not detected by PCR ampli¢cation (F|g. 1, Table 1 ). Kox1015, isolated from Patient 1 after 10 days of meropenem therapy, was found to have an MIC to meropenem of 1 mg/mL (susceptible) by V|tek 2 but 8 mg/mL (intermediate) by microbroth dilution (Table 1) . Kpn1016 had an MIC to meropenem of ! 16 mg/mL (resistant) by V|tek 2 and 4 mg/ mL (susceptible) by microbroth dilution (Table 1 ). Kpn1017 isolated from Patient 2, 35 days after isolating Kpn1016 from Patient 1, had an MIC to meropenem of 4 mg/mL (susceptible) by V|tek 2 and 16 mg/mL (resistant) by microbroth dilution (Table 1) . On disk di¡usion testing, the zones of inhibition for Kox1015, Kpn1016, and Kpn1017 (zone diameters 16^17 mm) were smaller than that for Kpn1014 but remained in the susceptible range. Recently, detection of CP-E by automated susceptibility testing systems has been shown to be greatly improved by using ertapenem rather than meropenem or imipenem as the class agent for carbapenems (16) . Kox1015, Kpn1016, and Kpn1017 had an MIC to ertapenem of 4 mg/mL or greater (nonsusceptible) by V|tek 2 and microbroth dilution (Table 1) . Kox1015, Kpn1016, and Kpn1017 also had positive modi¢ed Hodge and bla KPC -PCR tests (F|g. 1, Table 1 ). DNA sequencing con¢rmed that all isolates carried the bla KPC-2 allele.
Plasmids were extracted from the Klebsiella isolates and separated by gel electrophoresis. As shown in F|gure 2A, the plasmid pro¢les of Kpn1016 and Kpn1017 were identical, while those of Kpn1014 and Kox1015 di¡ered by several bands. Southern blot analysis using a bla KPC -speci¢c probe con¢rmed the presence of bla KPC plasmids in strains Kox1015, Kpn1016, and Kpn1017 but not Kpn1014 (F|g. 2B). Kpn1016 and Kpn1017 had a single plasmid of 54 kb that inton agar plate shortly after being inoculated with the carbapenemsensitive strain Escherichia coli ATCC 25922, and isolates Kpn1014 and Kpn1016 were struck radially from the disk to the plate edge. Kpn1014 is bla KPC-2 -negative and shows a concentric zone of growth inhibition at its intersection with ATCC 25922, whereas invagination of ATCC 25922 growth into the imipenem zone of inhibition adjacent to Kpn1016 is indicative of carbapenemase production.
hybridized to the bla KPC probe, while Kox1015 had 2 bla KPCpositive plasmid bands of approximately 80 and 110 kb.
PFGE of the K. pneumoniae isolates revealed that Kpn1014 was closely related to Kpn1016, di¡ering by a total of 3 bands, and that Kpn1016 and Kpn1017 belong to the same lineage (87% Dice similarity coe⁄cient) (F|g. 3). Kpn1016 and Kpn1017 were not related (o60% Dice similarity coe⁄cient) to other KPC-producing K. pneumoniae isolates in the Centers for Disease Control database, including archived strains obtained in 2005 from the Philadelphia hospital where Patient 1 was hospitalized early in his course (data not shown).
Discussion
This report highlights several challenges regarding the diagnosis and treatment of CP-E infections. F|rst, it demonstrates the di⁄culty in recognizing and verifying carbapenemase production in Enterobacteriaceae by clinical microbiology laboratories. In the United States, the KPC enzyme has emerged in a diverse array of Enterobacteriaceae, including K. pneumoniae, K. oxytoca, Enterobacter species, E. coli, Citrobacter freundii, and Salmonella enterica (17 ) . As seen in these cases, automated susceptibility testing can incorrectly report a KPC-producing organism as carbapenem sensitive (4, 16, 18) . In hospitals with no prior experience with CP-E, initial recognition of an enteric carbapenemase producer may only occur due to the consideration of an astute clinician or microbiologist. Second, the cases con¢rm that the treatment of CP-E infections with carbapenemases is associated with clinical and/or microbiological failure. Erroneous assignment as carbapenem susceptible may have grave clinical consequences. Third, unrecognized, undrained, or inaccessible collections may serve as a nidus for recurrent infection. Although not observed in these cases, retreatment of CP-E infections has the potential to further select for resistance in these isolates.
Twelve cases of invasive CP-E infection, including the 2 presented herein, have been reported in the English-language literature and are summarized in Table 2 (8, 19^23) . The cases included 7 liver, 3 kidney, and 1 heart transplant recipient; the organ transplanted was not reported in one case.Thirteen Enterobacteriaceae were cultured: 9 K. pneumoniae, 2 K. oxytoca, and 2 Enterobacter cloacae. Nine of the 12 cases involved bloodstream infection. In North America, all isolates (n 5 7) carried bla KPC , while in Europe the isolates (n 5 6), most from a single Italian hospital outbreak, carried bla VIM-1 . This pattern generally re£ects the current distribution of carbapenemases in Enterobacteriaceae, with a preponderance of KPC (serine) carbapenemases in North America and VIM-1 metallo-b-lactamases in Europe. The crude mortality rate was 58%; 6 of the 7 LT patients died. No clear relationship between the chosen antimicrobial regimen and survival could be determined.
Several factors place SOT recipients at high risk for infection by CP-E. F|rst, SOT recipients often receive prolonged courses of broad-spectrum antibiotics, an enormous selective pressure for the acquisition of antimicrobial-resistant organisms. Determinants of resistance, including KPC and VIM-1 carbapenemases, are often encoded on transposons or plasmids that carry suites of other resistance genes.Therefore, selective pressure occurs even with the use of unrelated classes of antibiotics. In this regard, it is instructive that Patient 2 developed bla KPC-2 -positive K. pneumoniae bacteremia without antecedent carbapenem therapy. Second, transplant recipients undergo numerous invasive therapeutic and diagnostic procedures. Technical complications, including early graft injury, as well as the intensity of immunosuppression, poor allograft function, and rejection, are particularly important risks for the development of nosocomial infections in the early posttransplant period (24, 25) . Third, SOT patients have high rates of hospitalization, which increase the risk of becoming colonized with healthcare-associated multidrug-resistant organisms such as CP-E. Intra-and interhospital 
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Transplant Infectious Disease 2009: 11: 257^265 transfers are common among organ transplant recipients and may geographically expand opportunities for crosscolonization by drug-resistant organisms. We speculate that the index patient may have become colonized with bla KPC-2 -containing Klebsiella during a hospitalization in Philadelphia, although PFGE failed to show genetic relatedness between his isolates and tested Philadelphia KPC-containing Klebsiella isolates. Alternatively, he may have acquired a strain during an earlier hospitalization that later served as a bla KPC-2 -plasmid or transposon donor. Infections in SOT patients and other immunocompromised hosts can provide sentinel warning of changes in pathogen tra⁄cking and dissemination, both in the hospital and the community (26, 27 ) . In this instance, the reported patients were the ¢rst cases of KPC-producing Enterobacteriaceae infection identi¢ed at our institution. A subsequent hospital-wide outbreak involving 2 dozen additional patients has been recognized and epidemiologically and/or microbiologically linked to the index cases, despite reinforced infection control education and monitoring e¡orts (A.J.M., H.L.C., K.C.H. and C.D.S., unpublished data). Similarly, in an Italian report describing an outbreak of VIM-1-producing K. pneumoniae bloodstream infections, the index case occurred in a kidney transplant recipient (8) .
These reports illustrate that SOT recipients can act not only as sentinels for new pathogens but also as conduits for their spread to new locations or facilities.
Unfortunately, the risk for continued CP-E dissemination will remain high because of suboptimal clinical laboratory recognition of carbapenem-resistance in enteric gram-negative bacilli (as demonstrated by the initial antibiotic susceptibility results in these cases), unrecognized 'silent' fecal carriage of CP-E, and environmental contamination. While susceptibility testing systems that use ertapenem as the class agent for carbapenems have been shown to be vastly improved at detecting CP-E, they are not infallible (16) . Other detection methods under investigation include the use of CHROMagar optimized for CP-E detection and the assessment of potentiation of carbapenem resistance by boronic acid compounds (28, 29) . The optimal method for detection and screening for carbapenemase production in Enterobacteriaceae remains to be de¢ned.
The optimal therapy for serious CP-E infection is also uncertain, and treatment of disease in SOT patients poses several additional challenges. Surgical debridement of devitalized tissue and drainage of collections remains a cornerstone for e¡ective treatment of local infections. Reducing the level of immunosuppression may also o¡er the best opportunity for control of these infections, especially in cases where overimmunosuppression may have been an important contributing factor, such as the cases presented here. CP-E isolates are routinely resistant to many classes of antibiotics, often leaving polymyxins and tigecycline as the only remaining antimicrobials with in vitro activity against these organisms (30) . In recent years, the polymyxins (colistin and polymyxin B) have been resurrected because of the emergence of carbapenem resistance in enteric and nonfermentative gram-negative bacilli. In the modern era, polymyxin-induced nephrotoxicity and neurotoxicity appears to be less common and severe compared with the historic experience (31) . However, polymyxin toxicities remain important clinical considerations, and whether these toxicities are more frequent or severe in transplant patients receiving calcineurin inhibitors (with their associated nephrotoxicty and neurotoxicty) remains to be determined.
Another concern is the emergence of polymyxin resistance in CP-E. Rates of polymyxin resistance in KPC-producing K. pneumoniae reached 9^27% during recent outbreaks in New York, and an outbreak of colistin-resistant, metallo-b-lactamase-producing K. pneumoniae has been reported in a Greek ICU (18, 32, 33) .We believe that use of polymyxins for selective bowel decontamination before LT should be abandoned; not only is it doubtful that the practice reduces postoperative infections, but it is also unambiguously linked to the development of colistin resistance (34^36).
T|gecycline is a new semisynthetic glycylcycline antibiotic that has in vitro activity against a broad array of nosocomial pathogens, including most Enterobacteriaceae, and is approved for the treatment of complicated skin and skin structure and complicated intra-abdominal infections (37 ) . A recent survey of 104 CP-E isolates collected from medical centers located in North America, Europe, and Latin America failed to identify a single strain that was tigecycline resistant (38) . By contrast, 11.9% of the isolates were resistant to polymyxins. However, the e⁄cacy of tigecycline to treat CP-E infection (especially endovascular infection) has been questioned, and treatment-associated increases in tigecycline MICs have been observed during therapy (22, 39) . Furthermore, tigecycline is not active against Pseudomonas species and has reduced activity against genera of the tribe Proteeae (Proteus, Providencia, and Morganella). , colistin inhaled; GEN, gentamicin; IMP, imipenem; LEV, levo£oxacin; MER, meropenem; RIF, rifampin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline;TZP, tazobactam-piperacillin; VIM-1, metallo-beta-lactamase; KPC, K. pneumoniae carbapenamase. 3 Also bacteremic with KPC-2 producing Pseudomonas putida. In conclusion, carbapenem-resistant Enterobacteriaceae are perfectly suited to become important pathogens in SOT recipients. Once largely con¢ned to certain geographic areas, these organisms are rapidly spreading to new institutions and locations around the world. Unfortunately, few new agents are in the pipeline that may have activity against these pan-resistant organisms. In what has been described as a 'microbial perfect storm' of exploding drug resistance and neglected antibiotic development, pan-resistant CP-E and the specter of extreme drug resistant Enterobacteriaceae represent an enormous threat to solid organ transplantation (40, 41) . Strict infection control measures, aggressive antibiotic stewardship, and improved screening strategies will be needed to curtail their spread. Further research is urgently needed to determine the clinical impact and optimal therapeutic and prevention strategies for CP-E infection in organ transplantation.
